CARDIAC RHYTHM MANAGEMENT DEVICES BATTERIES MARKET ANALYSIS

Global Cardiac Rhythm Management Devices Batteries Market, By Product Type (Implantable Cardiac Pacemaker, Implantable Cardioverter Defibrillator, and Cardiac Resynchronization Device), By Power Source (Lithium-Iodine Cells, Lithium-Silver Vanadium Oxide Cell, Lithium-Carbon Monofluride Cells, and Lithium-Manganese Dioxide), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

New product approvals/launches

On October 23, 2023, Medtronic plc, a global leader in healthcare technology, had received the U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest (SCA)
On July 5, 2023, Abbott, a medical device company, announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms
In April 2022, BIOTRONIK, Inc., a medical device company, announced that it has received the U.S. Food and Drug Administration (FDA) approval of Renamic Neo, the company's state-of-the-art programmer for implanted cardiac rhythm management devices such as ICDs, pacemakers, and implantable cardiac monitors

Cardiac Rhythm Management Devices Batteries Market Report Snapshots